In ScienceDaily, Stanford Medicine research reports that they were able to design immune cells to attack childhood cancers that were able to eradicate different types of pediatric tumors in mice. Based on the results, the team is now planning a series of phase-1 clinical trials for the B7-H3 CAR-T cells, starting with adult brain tumor patients. B7-H3 is not expressed on healthy tissues in the central nervous system, making it a good starting point for human trials. Follow the link for the entire article.
Robbie Majzner, MD